2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow SARS-CoV-2 Vaccine: new trials by email Literature Review of SARS-CoV-2 Vaccine trials Research Report on SARS-CoV-2 Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age mRNA-1083, Placebo, Licensed Influenza Vaccine - COVID-19, Influenza | Phase 3 | Completed | ModernaTX, Inc. | 2457 | 2024-11-18 | 2025-12-02 |
| Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) 9vHPV Vaccine, mRNA-1273 Vaccine - Papillomavirus Infections, Coronavirus Disease (COVID-19) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 165 | 2022-03-28 | 2026-02-05 |
COVID-19 (2) · Influenza, Human (1) · Papillomavirus Infections (1)
Merck Sharp & Dohme LLC (1) · ModernaTX, Inc. (1)
Japan (1) · South Korea (1) · Taiwan (1) · United States (1)